“Liquid Biopsy Market” Led by Players Like Roche Diagnostics (US), Genomic Health, Inc. (US) and Thermo Fisher Scientific Inc. (US) by 2021

Press Release   •   Jan 09, 2018 06:54 EST

Key players operating in liquid biopsy market are Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.).

Complete report on Liquid Biopsy Market spread across 160 Pages, Profiling 11 Companies and Supported with 75 Tables and 74 Figures is now available at http://www.rnrmarketresearch.com/contacts/request-sample?rname=640498 .

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during forecast period of 2016 to 2021. Technological advancements, increasing number of new cancer cases, availability of funding, growing awareness about liquid biopsy through conferences and government initiatives, and benefits of liquid biopsy over solid tumor biopsy are some of major factors driving growth of market.

Target Audience:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Institutes
  • Contract Research Organizations
  • Research and Consulting Companies
  • Liquid Biopsy Product Manufacturers and Distributors
  • Hospitals and Diagnostics Centers
  • Reference Laboratories
  • Government and Public Laboratories

Liquid biopsy market classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. Other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Detailed insights on the upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Click Here For More Information with Company Profiles and Top Trends at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=640498 .

The liquid biopsy market is segmented based on cancer type, circulating biomarkers, products & services, end users, and regions. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer).

Premium Insights

1 Liquid Biopsy: Market Overview

2 Geographic Analysis: Liquid Biopsy Market, By Circulating Biomarker

3 Market Size, By End User,

4 Market Size, By Product,

5 Market Size, By Circulating Biomarker,

6 Geographical Snapshot of the Market

Click now for more Details, Queries and Corporate Order on this study “Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021” report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=640498 .

Lung cancer segment is expected to account for the largest share of liquid biopsy market primarily due to technological advancements and the growing demand for advanced diagnostic technologies among the large base of lung cancer patients.

A number of factors, such as technological advancements, increasing number of new cancer cases, benefits of liquid biopsy over solid tumor biopsy, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market.

Contact sales@rnrmarketresearch.com / Call +1 888 391 5441 for further information and more details with intelligence needs for your business. Access to in-depth market trends helps companies to assess the market effectiveness. Market research studies several features of business environment, such as competitors, market structure, government regulations, economic trends, technological advances and financial analysis of companies, industries, and sectors.